Mark Leonard Singleton - 10 Apr 2023 Form 4 Insider Report for Bioventus Inc. (BVS)

Role: SVP & CFO
Signature: /s/Anthony D'Adamio, Attorney-in-Fact
Issuer symbol: BVS
Transactions as of: 10 Apr 2023
Net transactions value: $0
Form type: 4
Filing time: 12 Apr 2023, 21:14:53 UTC
Previous filing: 27 Mar 2023
Next filing: 22 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	BVS	Class A Common Stock						12,581	10 Apr 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BVS	Restricted Stock Units	Award	$0	+52,000		$0.000000	52,000	10 Apr 2023	Class A Common Stock	52,000		Direct	F1, F2
transaction	BVS	Stock Option (Right to Buy)	Award	$0	+135,800		$0.000000	135,800	10 Apr 2023	Class A Common Stock	135,800	$1.16	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2	The RSUs and options, as applicable, shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date.